Related Experiment Video
Updated: Oct 2, 2026

Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma
Jason M Shohet1, M John Hicks, Sharon E Plon
1Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
The MYCN oncogene is amplified in approximately 25% of neuroblastoma tumors and is the most significant negative prognostic factor. The direct transcriptional targets of MYCN in MYCN-amplified tumors have not been defined. Microarray analysis of RNA from neuroblastoma primary cell cultures revealed 10-fold higher MCM7 expression in MYCN-amplified versus nonamplified tumors. MCM7 is an essential component of DNA replication licensing factor, a hexameric protein complex that regulates DNA synthesis during the cell cycle, preventing rereplication and ensuring maintenance of DNA euploidy. Additional experiments demonstrated markedly increased expression of MCM7 RNA and protein in MYCN-amplified neuroblastoma tumors and cell lines. Induction of MYCN in conditional cell lines results in increased expression of endogenous MCM7 mRNA and a 3-fold increase in protein levels. In addition, luciferase activity from MCM7 promoter/luciferase gene reporter constructs was significantly increased under MYCN-induced conditions. Specific electrophoretic mobility shifts of MCM7 promoter sequences are detected in extracts of MYCN-amplified cells. These findings demonstrate that in neuroblastoma, the MYCN oncogene directly activates genes required for DNA replication, and this may contribute to neoplastic transformation of these MYCN-amplified tumors.
Insights
The MYCN oncogene directly increases MCM7 expression in neuroblastoma, a key protein for DNA replication. This finding sheds light on how MYCN drives tumor growth in these cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MYCN oncogene amplification is a major negative prognostic factor in neuroblastoma.
- Direct transcriptional targets of MYCN in neuroblastoma remain largely undefined.
- Understanding MYCN's regulatory network is crucial for developing targeted therapies.
Purpose of the Study:
- To identify direct transcriptional targets of the MYCN oncogene in neuroblastoma.
- To investigate the role of MCM7 in MYCN-amplified neuroblastoma.
- To elucidate the mechanism by which MYCN influences DNA replication genes.
Main Methods:
- Microarray analysis of RNA from neuroblastoma cell cultures.
- Quantitative analysis of MCM7 RNA and protein expression.
- Luciferase reporter assays to assess promoter activity.
- Electrophoretic mobility shift assays (EMSA) to detect protein-DNA interactions.
Main Results:
- MCM7 expression was 10-fold higher in MYCN-amplified neuroblastoma tumors compared to non-amplified tumors.
- MCM7 RNA and protein levels were significantly increased in MYCN-amplified neuroblastoma cell lines and tumors.
- MYCN induction in conditional cell lines led to increased MCM7 mRNA and protein levels.
- Luciferase activity assays and EMSA confirmed direct transcriptional activation of MCM7 by MYCN.
Conclusions:
- The MYCN oncogene directly activates MCM7, an essential gene for DNA replication, in neuroblastoma.
- This direct activation of DNA replication genes by MYCN may contribute to neoplastic transformation and tumor progression.
- Targeting the MYCN-MCM7 axis could represent a novel therapeutic strategy for MYCN-amplified neuroblastoma.
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic cells are...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs
